Correlation Between Performance-Based and Interview-Based Cognitive Measurements in Patients with Schizophrenia

Overview

Journal Psychiatry Investig

Specialty Psychiatry

Date 2020 Jul 8

PMID 32631031

Citations 1

Authors

Dong-Wook Jeon

Do-Un Jung

Minkyung Oh

Jung-Joon Moon

Sung-Jin Kim

Yeon-Sue Kim

Affiliations

Soon will be listed here.

Abstract

Objective: The Measurement and Treatment Research to improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) is used to measure the cognitive function of patients with schizophrenia. In some situations, interview-based measures such as the Schizophrenia Cognition Rating Scale (SCoRS) may be appropriate. In this study, we analyzed the correlation between performance- and interview-based measurements in patients with schizophrenia.

Methods: Fifty-six clinically stable patients were recruited. To evaluate cognitive function, we used the MCCB performance-based measure and the SCoRS interview-based measure. Measurements were taken at baseline, and 2 weeks and 3 months later. Spearman correlations were computed between each SCoRS item's interviewer rating and each MCCB score.

Results: The correlation between the MCCB overall T score and the SCoRS global score was the strongest (r=-0.52), while the SCoRS total score and the MCCB Speed of Processing score also correlated (r=-0.48). The SCoRS global score showed statistically significant correlations with all seven MCCB domains and the overall T score.

Conclusion: This study reveals correlations between MCCB domains and SCoRS items. Since we find that interview-based measurements are highly correlated with performance-based measurements, we suggest them as a useful cognitive function evaluation tool that can easily be applied in clinical settings.

Citing Articles

Validation of the Chinese Version of the Schizophrenia Cognition Rating Scale.

Huang K, Lin P, Lee Y, Huang Y, Hung C, Lee S Psychiatry Investig. 2022; 19(7):511-518.

PMID: 35903053 PMC: 9334803. DOI: 10.30773/pi.2021.0322.

References

Rey M, Schulz P, Costa C, Dick P, Tissot R . Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol. 1989; 4(2):95-104. DOI: 10.1097/00004850-198904000-00001. View

Kang E, Kim S, Seo Y, Jung S, Seo B, Ryu J . The Korean Version of the Schizophrenia Cognition Rating Scale: Reliability and Validity. Psychiatry Investig. 2017; 14(2):141-149. PMC: 5355011. DOI: 10.4306/pi.2017.14.2.141. View

Chia M, Chan W, Chua K, Lee H, Lee J, Lee R . The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. Psychiatry Res. 2010; 178(1):33-8. DOI: 10.1016/j.psychres.2010.03.020. View

Burton C, Vella L, Harvey P, Patterson T, Heaton R, Twamley E . Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia. Schizophr Res. 2013; 146(1-3):244-8. PMC: 3740948. DOI: 10.1016/j.schres.2013.02.026. View

Keefe R, Davis V, Spagnola N, Hilt D, Dgetluck N, Ruse S . Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. Eur Neuropsychopharmacol. 2014; 25(2):176-84. PMC: 4277931. DOI: 10.1016/j.euroneuro.2014.06.009. View

Palmer B, Heaton R, Paulsen J, Kuck J, Braff D, Harris M . Is it possible to be schizophrenic yet neuropsychologically normal?. Neuropsychology. 1997; 11(3):437-46. DOI: 10.1037//0894-4105.11.3.437. View

Keefe R, Poe M, Walker T, Kang J, Harvey P . The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am J Psychiatry. 2006; 163(3):426-32. DOI: 10.1176/appi.ajp.163.3.426. View

Dickinson D, Ragland J, Calkins M, Gold J, Gur R . A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr Res. 2006; 85(1-3):20-9. PMC: 4332573. DOI: 10.1016/j.schres.2006.03.003. View

Higuchi Y, Sumiyoshi T, Seo T, Suga M, Takahashi T, Nishiyama S . Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version. Schizophr Res Cogn. 2017; 7:13-18. PMC: 5514300. DOI: 10.1016/j.scog.2017.01.001. View

10.

Jeon D, Jung D, Kim S, Shim J, Moon J, Seo Y . Adjunct transcranial direct current stimulation improves cognitive function in patients with schizophrenia: A double-blind 12-week study. Schizophr Res. 2019; 197:378-385. DOI: 10.1016/j.schres.2017.12.009. View

11.

Balzan R, Neaves A, Denson L, Liu D, Galletly C . Cognitive deficit awareness in schizophrenia: absent, intact, or somewhere in-between?. Cogn Neuropsychiatry. 2014; 19(6):471-84. DOI: 10.1080/13546805.2014.909311. View

12.

Gardner D, Murphy A, ODonnell H, Centorrino F, Baldessarini R . International consensus study of antipsychotic dosing. Am J Psychiatry. 2010; 167(6):686-93. DOI: 10.1176/appi.ajp.2009.09060802. View

13.

Vita A, Deste G, Barlati S, De Peri L, Giambra A, Poli R . Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophr Res. 2013; 146(1-3):217-23. DOI: 10.1016/j.schres.2013.02.035. View

14.

Green M . Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu Rev Clin Psychol. 2007; 3:159-80. DOI: 10.1146/annurev.clinpsy.3.022806.091529. View

15.

Nuechterlein K, Green M, Kern R, Baade L, Barch D, Cohen J . The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008; 165(2):203-13. DOI: 10.1176/appi.ajp.2007.07010042. View

16.

Kay S, Fiszbein A, Opler L . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2):261-76. DOI: 10.1093/schbul/13.2.261. View

17.

Noh J, Kim J, Hong K, Kim N, Nam H, Lee D . Factor structure of the neurocognitive tests: an application of the confirmative factor analysis in stabilized schizophrenia patients. J Korean Med Sci. 2010; 25(2):276-82. PMC: 2811297. DOI: 10.3346/jkms.2010.25.2.276. View

18.

Haro J, Kamath S, Ochoa S, Novick D, Rele K, Fargas A . The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003; (416):16-23. DOI: 10.1034/j.1600-0447.107.s416.5.x. View

19.

Marder S, Davis J, Chouinard G . The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1998; 58(12):538-46. DOI: 10.4088/jcp.v58n1205. View

20.

Haig G, Bain E, Robieson W, Baker J, Othman A . A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia. Am J Psychiatry. 2016; 173(8):827-35. DOI: 10.1176/appi.ajp.2015.15010093. View